期刊文献+

硼替佐米联合甲基强的松龙治疗Waldenstrom巨球蛋白血症1例

暂未订购
导出
出处 《临床肿瘤学杂志》 CAS 2008年第12期1148-1149,共2页 Chinese Clinical Oncology
  • 相关文献

参考文献6

  • 1Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase Ⅱ study of the National Cancer Institute of Canada Clinical Trials Group [J]. J Clin Oncol, 2007, 25 (12) : 1570-1575.
  • 2Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248 [J]. Clin Cancer Res, 2007, 13(11) :3320-3325.
  • 3Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstr m's macroglobulinemia with bortezomib[ J]. Haematologica, 2005, 90(12) :1655 - 1658.
  • 4Mitsiades CS, Mitsiades N, Richardson PG, et al. Novel biologically based therapies for Waldenstrom's macroglobulinemia [ J ]. Semin Oncol, 2003, 30(2):309-312.
  • 5Belch A, Kouroukis CT, Crump M, et al. A phase Ⅱ study of bortezomib in mantle cell lymphoma : the National Cancer Institute of Canada Clinical Trials Group trial IND. 150[J]. Ann Oncol, 2007, 18(1) :116 - 121.
  • 6Strauss SJ, Maharaj L. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity[J]. J Clin Oncol, 2006, 24(13) :2105 -2012.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部